Patent ID: 6667328
Filing Date: 2003-12-23
Classification: A61K,A61P,C07D,Y10S

Abstract:
A method for the treatment of diabetes comprising administering to a patient in need thereof a therapeutically effective amount of a pharmaceutical composition comprising a 2-(N-cyanoimino)thiazolidin-4-one derivative represented by the following formula I, or a solvate or a pharmaceutically acceptable salt thereof, as an active ingredient, and a pharmaceutically acceptable carrier: wherein ring A represents a benzene ring, a condensed ring, or a heterocyclic ring, each of which may be substituted by one or more substituents selected from a straight or branched C1-C4 alkyl group, a haloalkyl group, a halogen atom or â€”OR5, R1 represents a single bond, an oxygen atom, a sulfur atom, a methyne group, a straight or branched C1-C4 alkylene or alkenylene group optionally substituted by a phenyl group, R6â€”X, Xâ€”R6, Xâ€”R6â€”X, R6â€”Xâ€”R6, â€”C(&boxH;O)â€”NR7â€” or â€”NR7â€”C(&boxH;O)â€”, R2 and R3 are the same or different and each represents a hydrogen atom, a C1-C4 alkyl group, â€”OR8 or a halogen atom, R4 represents a hydrogen atom or a C1-C4 alkyl group, R5 represents a hydrogen atom or a C1-C4 alkyl group, R6 represents a straight or branched C1-C4 alkylene or alkenylene group, R7 represents a hydrogen atom or a C1-C4 alkyl group, R8 represents a hydrogen atom, a C1-C4 alkyl group or an aralkyl group, X represents an oxygen atom or a sulfur atom, and the configuration of the exocyclic methylene group at 5-position of the thiazolidine ring includes both E- and Z-configuration.